Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,018 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The paradigm of IL-6: from basic science to medicine.
Naka T, Nishimoto N, Kishimoto T. Naka T, et al. Among authors: kishimoto t. Arthritis Res. 2002;4 Suppl 3(Suppl 3):S233-42. doi: 10.1186/ar565. Epub 2002 May 9. Arthritis Res. 2002. PMID: 12110143 Free PMC article. Review.
IL-6: from laboratory to bedside.
Kishimoto T. Kishimoto T. Clin Rev Allergy Immunol. 2005 Jun;28(3):177-86. doi: 10.1385/CRIAI:28:3:177. Clin Rev Allergy Immunol. 2005. PMID: 16129902 Review.
Interleukin 6: from bench to bedside.
Nishimoto N, Kishimoto T. Nishimoto N, et al. Among authors: kishimoto t. Nat Clin Pract Rheumatol. 2006 Nov;2(11):619-26. doi: 10.1038/ncprheum0338. Nat Clin Pract Rheumatol. 2006. PMID: 17075601 Review.
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab.
Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Murata N, van der Heijde D, Kishimoto T. Nishimoto N, et al. Among authors: kishimoto t. Ann Rheum Dis. 2007 Sep;66(9):1162-7. doi: 10.1136/ard.2006.068064. Epub 2007 May 7. Ann Rheum Dis. 2007. PMID: 17485422 Free PMC article. Clinical Trial.
Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.
Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, Kishimoto T. Nishimoto N, et al. Among authors: kishimoto t. Mod Rheumatol. 2009;19(1):12-9. doi: 10.1007/s10165-008-0125-1. Epub 2008 Nov 1. Mod Rheumatol. 2009. PMID: 18979150 Free PMC article. Clinical Trial.
3,018 results